INTRODUCTION
============

Vitamin C (ascorbic acid) is a water-soluble vitamin that must be consumed from external sources (primarily fruits and vegetables) because humans cannot synthesize it endogenously. In addition to being an anti-oxidant , vitamin C improves endothelial-dependent vascular function, reduces monocyte adhesion to endothelium, reduces vascular smooth muscle cell apoptosis, and impacts oxidative modification of low-density lipoprotein \[[@R1]\]. However, while diets high in fruits and vegetables are associated with reduced cardiovascular disease (CVD) risk \[[@R2]-[@R5]\], anti-oxidant vitamin supplements, including vitamin C, have failed to reduce CVD events in randomized trials \[[@R6],[@R7]\]. Additional evidence suggests there may be a differential impact on CVD between vitamin intake from supplements vs food \[[@R8]-[@R10]\]; however mechanistic pathways are not understood.

Previous studies have shown that carotid artery intimal medial thickness (IMT), measured by B-mode ultrasound, is a measure of pre-clinical atherosclerosis, and is a correlate of angiographically determined coronary atherosclerosis \[[@R11]\]. Progression of IMT is associated with conventional atherosclerotic risk factors \[[@R12]\] and CV events \[[@R12],[@R13]\]. We evaluated the relations between intake of vitamin C from supplements vs. food with progression of carotid artery IMT.

METHODS
=======

Study Population
----------------

The Los Angeles Atherosclerosis Study (LAAS), a prospective cohort study of employees with uniform health insurance from a large utility company, has been described previously \[[@R14],[@R15]\]. Briefly, women aged 45-60, and men aged 40-60 years at entry were randomly sampled from strata (5-year age, Hispanic/other, current smoker/other). All study subjects were recruited from the same company, from 4 different job categories: union, management, administrative, and other. Employees with diagnosed CVD or current treatment for cancer were excluded. Participation rate was 85%, resulting in a cohort of 573 participants in the baseline examination (1995-1996). Two follow-up examinations were conducted at 1.5 and 3 years from baseline. The Institutional Review Boards at Keck School of Medicine of the University of Southern California, and Cedars-Sinai Medical Center approved the study, and all subjects gave written informed consent prior to participation.

Vitamin Intake
--------------

During baseline visit, dietary vitamin C intake was measured as the mean of up to six 24 hour (hr) recalls using the Minnesota Nutrition Data System (NDS); three measurements (two weekdays and one weekend or holiday) were taken at baseline, and three at 1.5 year follow-up \[[@R16]\]. Intake of vitamin supplements was measured at baseline and at 1.5 year follow-up with a nurse-assisted questionnaire. Questions concerning frequency and mode of supplemental vitamin C intake were included. Questions asked whether participants were taking vitamin C and multivitamins. Dosage per tablet (for specific supplements, but not for multi-vitamins), number of tablets per week, and duration of use were also recorded. Quartiles of multi-vitamin intake were 1-2, 2.5-3.5, 4.5-6, and 7-25 tablets per week. Quintiles of Vitamin C from food were 17.9-54.1, 54.6-77.6, 77.8-104.6, 104.9-145.8, and 146.1-395.3 mg/day.

Measurement of Plasma Ascorbic Acid
-----------------------------------

Plasma ascorbic acid (reduced form, AA) was determined by the method of Kutnink *et al.* \[[@R17]\]. To prevent oxidation during sample storage, an equal volume of 5% or 10% meta-phosphoric acid was added to ethylenediaminetetraacetic acid- plasma(EDTA) \[[@R18]\], and samples were stored at -70 °C. The average storage time of samples before analysis averaged 1.2 years. Isoascorbic acid was used as an internal standard to compensate for losses of AA during sample processing. Assays were performed by a laboratory participating in the NCI (National Cancer Institute)/NIST (National Institute of Standards and Technology) Ascorbic Acid Quality Assurance Program (CV=6.9% from daily plasma pools). No decline in concentration with duration of storage was observed. Given the potentially strong disease effect of atherosclerosis on plasma AA levels \[[@R19]\] and the availability of plasma antioxidant levels only at baseline, plasma levels were used only for validation of baseline intake measures.

Measurement of Carotid IMT
--------------------------

The LAAS protocol for high resolution B-mode ultrasonographic measurement of IMT in the common carotid artery was used as previously described \[[@R15]\]. Briefly, IMT was measured bilaterally in two body positions (lateral and supine) using an ATL scanner (model UM4+, 7.5 MHz linear transducer). Average thickness over a 1 cm segment of the distal wall 25 mm proximal to the bulb was measured using automated edge-tracking software. A reproducibility study yielded a standard deviation of 22 µm for differences between repeated scans by different sonographers (CV= 2.8%) \[[@R14]\].

Other Measurements
------------------

Examinations were conducted in the morning (after an overnight fast) in a mobile unit driven to the worksite. Ethnicity, alcohol intake, cigarette habit, physical activity, medication use and medical history were collected with an interviewer-assisted questionnaire. The survey detailed the patients' smoking habits including duration and amount of cigarettes and cigars smoked as well as an estimation of second hand smoke exposure. Alcohol intake was quantified by glasses, cans, bottles, and/or shots of wine (10.8 gram/glass), beer (13.2 gram/can), and/or hard liquor (15.1 gram/shot) consumed. Physical activity was assessed by days per week that patients exercise. Blood pressure and body mass index (kg/m^2^) were measured by a research nurse with a standardized protocol \[[@R20]\].

STATISTICAL ANALYSIS
====================

Statistical analyses were performed using the maximum likelihood SAS procedure for mixed models (repeated measures with unconstrained covariance structure) \[[@R21]\]. Change in carotid IMT from baseline (μm/year) was regressed on quintiles of dietary intake and five groups of supplement intake (non-users and quartiles among users). Tests of linear trend were performed by placing the constraint β\'L=0, where β is a vector of coefficients for quintiles and L\' = (-1 -0.5 0 0.5 1). For purposes of graphic depiction and *a posteriori* inspection for non-linear dose-response patterns, least squares means and standard errors were also estimated.

Three models were estimated. *Model 1* included age in years, sex, sex by age interaction, logarithm of total energy intake, two categorical variables for supplement intake (vitamin C and low-dose multi-vitamins), categorical variables for dietary intake (vitamin C from food), and two continuous variables (tablets per week) for stress and therapeutic multiple vitamins. *Model 2* added the covariates of smoking habit (current, former smoker), ethnicity (Hispanic, Black, and Asian, non-Hispanic white and other), alcohol intake (quintiles), physical activity (quintiles of number of strenuous activity sessions per week), use of anti-hypertensive medication, use of lipid lowering medication, diagnosis of diabetes, and number of cold/flu episodes in the previous year. *Model 3* added the covariates of serum cholesterol level, systolic blood pressure and body mass index (kg/m^2^) as continuous variables. If dietary and supplement intake mediate their effects *via* pathways that include an impact on the biological variables in Model 3, then Model 3 may underestimate effects.

RESULTS
=======

Characteristics of the study subjects by supplement intake of vitamin C, low-dose multi-vitamins, and vitamin C intake from foodare shown in Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**.Vitamin C intake from food was strongly associated with male sex (Table **[2](#T2){ref-type="table"}**), possibly due to increased food intake among men. Non-smokers had a higher intake of vitamin C from food than smokers (p=0.006).Intake of low-dose multi-vitamins was moderately positively correlated with intake of vitamin C supplements, but did not reach statistical significance (p=0.21). Follow-up was conducted among 87% (n=500) of the cohort (480 persons at 1.5-years and 447 at 3-years). No significant differences in demographic characteristics (p\>0.10) between those who completed the study and subjects that were lost to follow-up.

Plasma AA at baseline increased with both dietary and supplemental vitamin C intake. Among persons with no intake of supplement containing vitamin C, plasma AA increased monotonically from) 26.3±21 to 39.1±19 (mean±SD) μmol/L across quintiles of vitamin C from food (P-trend\<0.001). After adjustment for intake of vitamin C from food, plasma AA among those who took vitamin C supplements was further elevated by 3.5±20, 14.8±16, 10.2±16, and 19.7±15 μmol/L across quartiles of vitamin C intake from vitamin C supplements (P-trend\<0.001).

IMT Progression and Internal Validity
-------------------------------------

Mean IMT at baseline was 665.5 μm (SD=98.3). Carotid IMT progressed 10.0±16.5 μm/year (mean±SD) among all those with follow-up (n=500; 87%) over three years. In a multivariate model including age and sex, progression rate for IMT was significantly increased with current cigarette smoking (p=0.01), serum cholesterol (p=0.03), and systolic blood pressure (p=0.01).

IMT and Vitamin C Supplement Intake
-----------------------------------

Progression rate of IMT among subjects reporting no intake of vitamin C supplements and those who did report use of supplements are presented in (Table **[3](#T3){ref-type="table"}** and Fig. **[1](#F1){ref-type="fig"}**) by supplement dose quartiles. Among persons in the highest quartile (857-5000 mg/day) of vitamin C supplement intake compared to those not consuming any vitamin C supplements, carotid IMT progression increased three-fold (20.3±2.6 versus 7.6±1.8 μm/year (mean±SD); p\<0.001).As intake of vitamin C supplements increased, IMT progression rate increased (p-trend=0.0009, Model 1). Adjustment for potential confounders in Models 2 and 3 did not alter this pattern (Table **[3](#T3){ref-type="table"}**).

Carotid IMT and Multi-vitamin Intake
------------------------------------

Intake of low-dose multi-vitamins was not significantly related to carotid IMT progression (p-trend=0.28, Table **[3](#T3){ref-type="table"}**). However, there was significantly less carotid IMT progression among participants reporting weekly intake of at least one tablet (first quartile), relative to participants who reported no use of low-dose multi-vitamins (p=0.07, Model 1). Adjustment for potential confounders reduced this difference, but it was not statistically significant (p=0.09 in Model 3). The second quartile of multi-vitamin supplement intake (about 3 tablets per week) was associated with reduced progression in all three models.

Carotid IMT and Vitamin C Intake from Food Only
-----------------------------------------------

The relations between vitamin C intake from food and IMT progression are presented in Table **[4](#T4){ref-type="table"}**. There were no significant linear trends across dietary intake quintiles; however, carotid IMT progression was reduced in the highest quintile of dietary vitamin C intake relative to the other four quintiles (-5.0±1.9 μm/year; p=0.008 in Model 1). This difference was reduced by adjustment (-3.6±1.8 μm/year; p=0.04 in Model 3), reflecting the correlation between smoking and vitamin C intake from food. Exclusion of subjects being treated for hypertension, dyslipidemia, and diabetes increased this difference (-4.6±1.9 μm/year; p=0.01 in Model 3).

Interactions
------------

Current smoking did not significantly modify the association of vitamin C supplements (p=0.12) with IMT progression. The adverse association of vitamin C supplement intake in the upper tertile of serum cholesterol level (≥6.0 mmol/L) was 2-fold greater than in the lower two tertiles (p=0.01). A marginal interaction was also observed between vitamin C supplement intake and use of anti-hypertensive medication (p=0.06), where the adverse association of vitamin C supplements on carotid IMT progression was doubled among anti-hypertensive medication users. Inclusion of both these interactions into the model yielded stronger effect modification (p=0.0002 for serum cholesterol and p=0.005 for anti-hypertensive medication).

DISCUSSION
==========

To our knowledge, this is the first study to report greater progression of carotid IMT in those who took vitamin C supplements, compared to a relatively less progression of carotid IMT among those with a greater vitamin C intake from food. The adverse association of vitamin C supplement intake was most evident in those subjects with elevated serum cholesterol level and among those with hypertension. The current results provide a potential mechanistic understanding for the differential effects of vitamin C in supplements compared to food.

The finding that vitamin C supplements had an adverse association with atherosclerosis, while vitamin C intake from food may be protective is consistent with studies that point to a differential impact between vitamin intake from food and vitamin intake from supplements \[[@R8]-[@R10]\]. For example, dietary vitamin E intake has been associated with beneficial effects \[[@R22],[@R23]\] and, at doses of 50 to 537 mg/day, no effect on CVD risk was seen \[[@R24]-[@R27]\], but a meta-analyses on high dose vitamin E supplementation has suggested harm \[[@R28]\]. In a meta-analysis of 14 cohort studies on vitamin C by Ye *et al.* showed that dietary intake of vitamin C (but not supplemental vitamin C) had an inverse association with coronary heart disease risk \[[@R4]\]. Several explanations for this difference between supplements vs. intake from food for vitamins exist. Studies have reported equal bioavailability of ascorbic acid from food vs. supplemental ascorbic acid from vitamins \[[@R29]-[@R31]\], and there is no distinction between the chemical structures of vitamin C from these two sources, but vitamin C from fruits and vegetables may be accompanied by interacting components and cofactors, such as carotenoids and flavonoids, that have beneficial effects compared to vitamin C supplements \[[@R32],[@R33]\]. This theory is supported by epidemiological studies that demonstrate low β-carotene concentrations increase the risk of cardiovascular disease mortality and that increased flavonoid intake from food is associated with decreased risk of heart disease and mortality \[[@R34]-[@R37]\]. These studies are mostly dietary observational trials therefore isolating the individual impact of each antioxidant is not possible. Furthermore, large prospective clinical trials evaluating carotenoids, flavonoids, and the other 8000 phenol derivatives that are found in fruits and vegetables that have antioxidant properties \[[@R32]\], independently are lacking.

The results of our study are consistent with several cardiovascular primary and secondary prevention studies that failed to show benefit with vitamin C supplementation, when used alone or as part of an anti-oxidant cocktail \[[@R6],[@R38]-[@R41]\]. Two large-scale randomized trials tested the individual effect of vitamin C supplements on primary CVD prevention and found no reduction in the incidence of major cardiovascular events \[[@R6],[@R7]\]. The Physicans' Health Study II, a randomized controlled trial, reported a lack of effect of vitamin C supplement on major CVD events in 14,641 US male physicians over an 8 year follow-up period \[[@R7]\]. Similarly, no CVD benefits of vitamin C supplement were observed in the Women's Antioxidant Cardiovascular Study in 8,171 high-risk women \[[@R6]\]. More recently, a large-scale, placebo-controlled, randomized trial reported a possible adverse interaction between vitamin C and the combination therapy with folic acid, vitamin B~6~, and vitamin B~12~ on the CVD events in a high-risk population of women over 7.3 years of follow-up \[[@R42]\]. The risk of CVD events for folic acid was higher among those receiving active vitamin C than those receiving placebo (p-value for interaction=0.03) \[[@R42]\]. Of note, vitamin supplementation (C, D, E) in general has not been shown to consistently reduce the risk of diseases, such as cancer, where theoretically the role of anti-oxidants vitamins should be beneficial \[[@R43]-[@R46]\].

When vitamin C supplements are administered in conjunction with other anti-oxidant supplements, effects on early atherosclerosis progression are inconsistent \[[@R23],[@R47],[@R48]\]. One study reported that combined vitamin C and E supplementscan slow down the progression of IMT in men \[[@R23]\], however a larger trial conducted on 1162 apparently healthy subjects found that carotid IMT was not different between participants who received a combination of vitamin C, E, beta-carotene, and selenium versus placebo \[[@R47]\]. Waters *et al.* \[[@R48]\] confirmedthat a high-dose antioxidant vitamin supplement of 800 IU of vitamin E and 1000 mg of vitamin C per day compared to placebo in post-menopausal women provided no reduction in CVD events; however, they showed an increase in all-cause mortality in post-menopausal women with anti-oxidant vitamin consumption compared to women with placebo (HR, 2.8; 95% CI 1.1-7.2). Notably, the dose of vitamin C in this study associated with an increase in all-cause mortality was 2-fold higher than other studies that did not find similar results. These observations mirror our finding of greater IMT progression in subjects with increased supplementary vitamin C intake.

Additional data suggest important adverse interactions between vitamin supplements and prescribed medications. An angiographic trial found that an antioxidant cocktail (including 500 mg vitamin C and 400 IU vitamin E) reduced the beneficial effect of statins and niacin on coronary atherosclerosis \[[@R49]\]. It was postulated that this effect may have been due to an adverse effect of the vitamin supplement on serum high-density lipoprotein (HDL) \[[@R50]\]. We observed an adverse association of vitamin C supplementation with carotid IMT progression among subjects with relatively higher serum cholesterol levels (p-value for interaction=0.01), however, because only a few of our subjects were taking cholesterol lowering medications such as fibrates, niacin, and low-potency statins, we were unable to evaluate this interaction. Our results suggest that possible adverse association of vitamin C supplements may be even larger in coronary patients with elevated cholesterol similar to the results by Cheung *et al.* \[[@R50]\].

Strengths of our study include longitudinal measurements of early atherosclerosis concurrent with rigorously measured supplement and dietary vitamin C intake. The focus on early atherosclerosis avoids changes of intake in response to diagnosis, and concurrent measurement reduces the dilution of associations that occurs when baseline measurements of time-varying characteristics are related to future events. Confidence in the validity of measurements was enhanced by IMT reproducibility \[[@R15]\] and validation of self-reported dietary intake by plasma levels of AA. In addition, the high prevalence of supplement use and a wide range of intake levels in this Southern California cohort increased statistical power. The high participation rate after stratified random sampling from a population with uniform health insurance avoids numerous potential confounding factors. Confidence in the reliability of the observed associations between supplement intake and carotid IMT progression is supported by the consistency of findings across sexes and smoking status.

STUDY LIMITATIONS
=================

Due to the observational design of our study, there are inherent limitations. Unmeasured factors may be confounded with measured intake of supplements and food, or residual confounding by poorly measured risk factors may dilute covariate adjustments \[[@R21]\]. For example, the reduction in carotid IMT progression observed in the highest quintile of dietary vitamin C intake was attenuated by adjustment for smoking is suggestive of residual confounding. Previous studies have shown that smokers tend to have lower levels of Vitamin C, and therefore the recommended dietary allowance of Vitamin C for smokers is higher \[[@R51]\]. There was no clear pattern of association between supplement intake and lifestyle or biological CV risk factors, which argues against confounding by a general \"healthy lifestyle\" factor. In addition, data regarding supplement use and dietary patterns were obtained through memory recall which may be error prone.The present study was only an anatomic assessment of IMT; therefore, we cannot draw conclusions about plaque morphology or metabolism, which impacts stability of the plaque and causes CV events.

CONCLUSIONS
===========

In summary, our findings suggest that intake of vitamin C supplements has an adverse association with early atherosclerosis while dietary vitamin C from food has a protective association. Our results further suggest that the adverse association of vitamin C supplements may be relatively greater among subjects with elevated cholesterol levels. The current results provide a potential mechanistic understanding for the observed differences between Vitamin C in supplements vs food in prior studies. Based on our observations, vitamin C supplementation does not appear to be currently advisable for the prevention or treatment of CVD.
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###### 

Baseline Characteristics of Participants by Vitamin C Supplement intake and Low-dose Multi-Vitamin Supplement Intake. LAAS, 1994-1999 (N=500)

                                                           Vitamin C Supplement Intake (By Quartile)   P-value                           
  -------------------------------------------------------- ------------------------------------------- --------- ------- ------- ------- -------
  Sample Size (n)                                          309                                         48        51      50      42      
  Intake (mg/day)                                                                                                                        
   Minimum                                                 0                                           14        179     375     857     
   Maximum                                                 0                                           143       357     750     5000    
  Potential Confounders                                                                                                                  
   Sex (% women)                                           43.4                                        43.8      60.8    50      50      0.20
   Current smokers (%)                                     28.2                                        22.9      27.5    28      23.8    0.93
  Mean                                                                                                                                   
   Age at Baseline (year)                                  49.5                                        50.2      50.1    50.6    50.8    0.25
   Physical Activity (Sessions/wk)                         2.1                                         2.4       2.3     2.2     2.2     0.96
   Alcohol Intake (g/day)                                  6.9                                         8         7.6     5.2     7.7     0.74
   Cold/flu (episodes/year)                                1.02                                        1.16      1.18    1.06    1.05    0.71
   Serum Cholesterol (mmol/L)                              5.65                                        5.31      5.51    5.67    5.69    0.16
   Systolic Blood Pressure (mmHg)                          128.3                                       125.9     131     128     125.4   0.19
   Carotid IMT at baseline(µm)                             667                                         672       665     655     660     0.90
  Sample Size (n)                                          271                                         52        90      28      59      
  Intake (tablets/wk**[†](#T1F1){ref-type="table-fn"}**)                                                                                 
   Minimum                                                 0                                           1.0       2.5     4.5     7.0     
   Maximum                                                 0                                           2.0       3.5     6.0     24.5    
  Potential Confounders                                                                                                                  
   Sex (% women)                                           40.6                                        51.9      55.6    46.4    54.2    0.07
   Current smokers (%)                                     30.3                                        28.8      22.2    14.3    25.4    0.30
  Mean                                                                                                                                   
   Age at Baseline (year)                                  49.4                                        49.7      50.6    50.2    50.5    0.20
   Physical Activity (Sessions/wk)                         2.1                                         2.2       2.1     2.2     2.9     0.10
   Alcohol Intake (g/day)                                  7.8                                         4.8       6.1     5.8     7.2     0.33
   Cold/flu (episodes/year)                                1.05                                        1.16      1.08    1       0.97    0.81
   Serum Cholesterol (mmol/L)                              5.65                                        5.45      5.68    5.37    5.56    0.34
   Systolic Blood Pressure (mmHg)                          129                                         121.8     128.5   128.1   128.9   0.006
   Carotid IMT at baseline(µm)                             679                                         645       652     647     651     0.03

Quartiles of multiple vitamin intake were 1-2, 2.5-3.5, 4.5-6 and 7-25 tablets per week. Uneven numbers arise from averaging reports at two examinations.

###### 

Characteristics of the Los Angeles Atherosclerosis Study (LAAS) Subjects by Quintile of Vitamin C Intake from Food. Data are from LAAS, 1994-1999 (N=500)

                                     Vitamin C Intake from food (By Quintile)   P-value                           
  ---------------------------------- ------------------------------------------ --------- ------- ------- ------- --------
  Sample Size (n)                    96                                         101       106     100     97      
  Intake (mg/day)                                                                                                 
   Minimum                           17.9                                       54.6      77.8    104.9   146.1   
   Maximum                           54.1                                       77.6      104.6   145.8   395.3   
  Potential Confounders                                                                                           
   Sex (% women)                     66.7                                       41.6      48.1    45.0    30.9    0.0001
   Current smokers (%)               40.6                                       28.7      26.4    23.0    17.5    0.006
  Mean                                                                                                            
   Age at Baseline (year)            50.1                                       49.6      50.6    49.9    48.9    0.14
   Physical Activity (Sessions/wk)   2.1                                        2.0       2.1     2.2     2.5     0.39
   Alcohol Intake (g/day)            7.6                                        7.6       6.2     6.0     7.7     0.67
   Cold/flu (episodes/year)          1.06                                       1.12      1.01    0.98    1.13    0.68
   Serum Cholesterol (mmol/L)        5.62                                       5.75      5.52    5.53    5.63    0.43
   Systolic Blood Pressure (mmHg)    128.5                                      128.8     128     129.2   125.8   0.36
   Carotid IMT at baseline (µm)      659                                        668       670     672     657     0.75

###### 

Progression of Carotid Intima-Media Thickness (IMT, µm/year) by Quartile of Vitamin C and low-dose Multi-vitamin Supplement Intake. Data are from the Los Angeles Atherosclerosis Study (LAAS), 1994-1999 (N=500)

  Carotid Intima-Media Thickness (IMT)       Quartiles of Supplement Intake   P-value[‡](#T3F2){ref-type="table-fn"}                                                                
  ------------------------------------------ -------------------------------- ---------------------------------------- ------------------------------------------ -------- -------- --------
  (+) Vitamin C Supplement Intake                                                                                      Difference from Those Not on Supplements                     
   Mean (µm/year)                            9.0                              1.3                                      2.1                                        0.5      7.5      
    Standard Error                           0.9                                                                                                                                    
   Model 1[\*](#T3F1){ref-type="table-fn"}                                    1.9                                      4.1                                        1.9      12.3     0.0009
    Standard Error                                                            2.6                                      2.7                                        2.8      3.0      
    P-value (vs. No Vitamin C Supplements)   0.46                             0.13                                     0.49                                       0.0001            
   Model 2                                                                    2.6                                      4.8                                        3.2      12.5     0.0005
    Standard Error                                                            2.6                                      2.6                                        2.8      3.0      
    P-value                                                                   0.32                                     0.07                                       0.25     0.0001   
   Model 3                                                                    3.2                                      3.9                                        3.3      12.7     0.0005
    Standard Error                                                            2.6                                      2.6                                        2.7      3.0      
    P-value                                                                   0.22                                     0.14                                       0.23     0.0001   
                                                                                                                                                                                    
  (+) Multi-Vitamin Supplement Intake                                                                                  Difference from Those Not on Supplements                     
   Mean (µm/year)                            12.0                             -4.6                                     -4.9                                       -3.3     -3.7     
    Standard Error                           1.0                                                                                                                                    
   Model 1                                                                    -4.5                                     -5.1                                       -3.6     -3.8     0.28
    Standard Error                                                            2.5                                      2.0                                        3.2      2.4      
    P-value (vs. First Quintile)                                              0.07                                     0.01                                       0.27     0.11     
   Model 2                                                                    -5.2                                     -5.4                                       -3.4     -3.5     0.4
    Standard Error                                                            2.5                                      2.0                                        3.2      2.3      
    P-value                                                                   0.03                                     0.007                                      0.29     0.136    
   Model 3                                                                    -4.2                                     -5.4                                       -2.6     -3.4     0.39
    Standard Error                                                            2.4                                      2.0                                        3.1      2.3      
    P-value                                                                   0.09                                     0.006                                      0.41     0.14     

Model 1 was adjusted for age at baseline, sex, other supplements, intake of vitamin C and E from food and total energy intake. Model 2 added adjustment for ethnicity (non-Hispanic white, Hispanic, Black, Asian, other), alcohol intake (quintiles), vigorous physical activity (quintiles), treatment with anti-hypertensive medication, treatment with cholesterol lowering medication, diabetes (Type I or II), and frequency of colds or flu. Model 3 added adjustment for serum cholesterol, systolic blood pressure and body mass index.

Rate of IMT progression was reduced among multiple vitamin supplementers (combining across dose groups) relative to non-supplementers (p≤0.01 in all three models).

###### 

Progression of Common Carotid Intima-media Thickness (IMT, µm/year) by Quintile of Intake of Vitamin C from the Diet. Data are from the Los Angeles Atherosclerosis Study, 1994-1999 (n=500)

  Carotid Intima-Media Thickness (IMT)       Quintiles of Vitamin C Intake from Food   P-value[†](#T4F2){ref-type="table-fn"}                        
  ------------------------------------------ ----------------------------------------- ---------------------------------------- ------ ------ ------ ------
   Mean (µm/year)                            8.5                                       2.2                                      3.7    2.4    -1.1   
     Standard Error                          1.7                                                                                                     
   Model 1[\*](#T4F1){ref-type="table-fn"}                                             0.7                                      2.5    0.2    -4.1   0.11
     Standard Error                                                                    2.3                                      2.3    2.4    2.5    
    P-value (vs. First Quintile)             0.76                                      0.28                                     0.93   0.10          
   Model 2                                                                             1.1                                      4.0    1.4    -2.1   0.5
     Standard Error                                                                    2.3                                      2.3    2.4    2.5    
    P-value                                                                            0.63                                     0.08   0.56   0.41   
   Model 3                                                                             1.2                                      4.6    1.6    -1.8   0.57
     Standard Error                                                                    2.3                                      2.3    2.3    2.5    
    P-value                                                                            0.6                                      0.04   0.5    0.47   

For definitions of Models 1, 2 and 3, see notes to Table [2](#T2){ref-type="table"}.

Rate of IMT progression was reduced in the top quintile of vitamin C intake relative to the other four quintiles (p=0.008, 0.05 and 0.04 in Models 1, 2 and 3, respectively).
